NCT06518876 - A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

POEMS Syndrome

Interventions

BIOLOGICAL

KQ-2003 CAR T-cells

KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.

Trial Locations (1)

100730

Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing